Economic burden of joint analysis in psoriasis: US claims analysis
Few studies have assessed the economic burden of concomitant joint disease in patients with psoriasis (PSO). This analysis compared health care resource utilization (HCRU) and health care costs in patients with PSO vs those with psoriatic arthritis (PsA). This was a retrospective database analysis o...
Gespeichert in:
| Veröffentlicht in: | The American journal of managed care 2021-12, Vol.27 (12), p.e406-e412 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e412 |
|---|---|
| container_issue | 12 |
| container_start_page | e406 |
| container_title | The American journal of managed care |
| container_volume | 27 |
| creator | Prince, Patricia Skornicki, Michelle Suruki, Robert Lee, Edward Louder, Anthony |
| description | Few studies have assessed the economic burden of concomitant joint disease in patients with psoriasis (PSO). This analysis compared health care resource utilization (HCRU) and health care costs in patients with PSO vs those with psoriatic arthritis (PsA).
This was a retrospective database analysis of US commercially insured patients with PSO or PsA.
Electronic health records (EHRs) and claims in Optum's deidentified Integrated Claims-Clinical data set from 2007 to 2018 were analyzed. Patients were followed up from the first PSO or PsA diagnosis for up to 5 years. Patients with claims or diagnosis codes in EHR data for PSO ("PSO only") were propensity score matched to patients with claims/diagnosis codes for both PSO and PsA ("PSO-PsA").
The matching algorithm generated 4418 matched patient pairs. During follow-up, PSO-PsA patients had greater HCRU than PSO-only patients, including more cumulative all-cause outpatient claims (P ≤ .05 at each year of follow-up). Mean total annual health care costs per patient were higher in PSO-PsA patients than PSO-only patients (PSO only: $14,546-$15,800 vs PSO-PsA: $21,581-$22,868; P |
| doi_str_mv | 10.37765/ajmc.2021.88768 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2608540765</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2608540765</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1442-be82daa94a91739d4ab3ba275b978d617fad3780705f14024d643f51939ea3673</originalsourceid><addsrcrecordid>eNo9kElPwzAQRi0EoqVw54R85JLgLV64QVUWqRIH6NmaOI7kKolL3Bz670kXepoZ6X2fNA-he0pyrpQsnmDdupwRRnOtldQXaEoNlxmThl2OO9E6I4yJCbpJaU0Il1rIazThQmtTaDZFrwsXu9gGh8uhr3yHY43XMXRbDB00uxQSDh3epNgHGI9nvPrGroHQpjNwi65qaJK_O80ZWr0tfuYf2fLr_XP-sswcFYJlpdesAjACDFXcVAJKXgJTRWmUriRVNVRcaaJIUVNBmKik4HUx_mM8cKn4DD0eezd9_B182to2JOebBjofh2SZJLoQZNQyouSIuj6m1PvabvrQQr-zlNiDObs3Z_fm7MHcGHk4tQ9l66tz4F8V_wMIZWjn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2608540765</pqid></control><display><type>article</type><title>Economic burden of joint analysis in psoriasis: US claims analysis</title><source>ProQuest Central Essentials</source><source>Research Library</source><source>MEDLINE</source><source>ProQuest Central (Alumni Edition)</source><source>ProQuest Central Student</source><source>Research Library (Alumni Edition)</source><source>Research Library Prep</source><source>ProQuest Central Korea</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>ProQuest Central</source><creator>Prince, Patricia ; Skornicki, Michelle ; Suruki, Robert ; Lee, Edward ; Louder, Anthony</creator><creatorcontrib>Prince, Patricia ; Skornicki, Michelle ; Suruki, Robert ; Lee, Edward ; Louder, Anthony</creatorcontrib><description>Few studies have assessed the economic burden of concomitant joint disease in patients with psoriasis (PSO). This analysis compared health care resource utilization (HCRU) and health care costs in patients with PSO vs those with psoriatic arthritis (PsA).
This was a retrospective database analysis of US commercially insured patients with PSO or PsA.
Electronic health records (EHRs) and claims in Optum's deidentified Integrated Claims-Clinical data set from 2007 to 2018 were analyzed. Patients were followed up from the first PSO or PsA diagnosis for up to 5 years. Patients with claims or diagnosis codes in EHR data for PSO ("PSO only") were propensity score matched to patients with claims/diagnosis codes for both PSO and PsA ("PSO-PsA").
The matching algorithm generated 4418 matched patient pairs. During follow-up, PSO-PsA patients had greater HCRU than PSO-only patients, including more cumulative all-cause outpatient claims (P ≤ .05 at each year of follow-up). Mean total annual health care costs per patient were higher in PSO-PsA patients than PSO-only patients (PSO only: $14,546-$15,800 vs PSO-PsA: $21,581-$22,868; P < .05 at each year of follow-up). All-cause outpatient and pharmacy costs were also higher in the PSO-PsA cohort (P < .05 at each year of follow-up).
Comorbid joint disease in PSO is associated with greater costs and use of health care resources than PSO alone. These findings underscore the need for dermatologists to be vigilant about detection and treatment of joint symptoms. Early PsA diagnosis and therapy are crucial to improve patient outcomes and reduce the potential economic burden.</description><identifier>ISSN: 1088-0224</identifier><identifier>EISSN: 1936-2692</identifier><identifier>DOI: 10.37765/ajmc.2021.88768</identifier><identifier>PMID: 34889582</identifier><language>eng</language><publisher>United States</publisher><subject>Arthritis, Psoriatic - diagnosis ; Arthritis, Psoriatic - epidemiology ; Financial Stress ; Humans ; Insurance Claim Review ; Psoriasis - diagnosis ; Psoriasis - epidemiology ; Retrospective Studies</subject><ispartof>The American journal of managed care, 2021-12, Vol.27 (12), p.e406-e412</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1442-be82daa94a91739d4ab3ba275b978d617fad3780705f14024d643f51939ea3673</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,33453,33531,33704,33745,34006,34315,34335,36266,64387</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34889582$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Prince, Patricia</creatorcontrib><creatorcontrib>Skornicki, Michelle</creatorcontrib><creatorcontrib>Suruki, Robert</creatorcontrib><creatorcontrib>Lee, Edward</creatorcontrib><creatorcontrib>Louder, Anthony</creatorcontrib><title>Economic burden of joint analysis in psoriasis: US claims analysis</title><title>The American journal of managed care</title><addtitle>Am J Manag Care</addtitle><description>Few studies have assessed the economic burden of concomitant joint disease in patients with psoriasis (PSO). This analysis compared health care resource utilization (HCRU) and health care costs in patients with PSO vs those with psoriatic arthritis (PsA).
This was a retrospective database analysis of US commercially insured patients with PSO or PsA.
Electronic health records (EHRs) and claims in Optum's deidentified Integrated Claims-Clinical data set from 2007 to 2018 were analyzed. Patients were followed up from the first PSO or PsA diagnosis for up to 5 years. Patients with claims or diagnosis codes in EHR data for PSO ("PSO only") were propensity score matched to patients with claims/diagnosis codes for both PSO and PsA ("PSO-PsA").
The matching algorithm generated 4418 matched patient pairs. During follow-up, PSO-PsA patients had greater HCRU than PSO-only patients, including more cumulative all-cause outpatient claims (P ≤ .05 at each year of follow-up). Mean total annual health care costs per patient were higher in PSO-PsA patients than PSO-only patients (PSO only: $14,546-$15,800 vs PSO-PsA: $21,581-$22,868; P < .05 at each year of follow-up). All-cause outpatient and pharmacy costs were also higher in the PSO-PsA cohort (P < .05 at each year of follow-up).
Comorbid joint disease in PSO is associated with greater costs and use of health care resources than PSO alone. These findings underscore the need for dermatologists to be vigilant about detection and treatment of joint symptoms. Early PsA diagnosis and therapy are crucial to improve patient outcomes and reduce the potential economic burden.</description><subject>Arthritis, Psoriatic - diagnosis</subject><subject>Arthritis, Psoriatic - epidemiology</subject><subject>Financial Stress</subject><subject>Humans</subject><subject>Insurance Claim Review</subject><subject>Psoriasis - diagnosis</subject><subject>Psoriasis - epidemiology</subject><subject>Retrospective Studies</subject><issn>1088-0224</issn><issn>1936-2692</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kElPwzAQRi0EoqVw54R85JLgLV64QVUWqRIH6NmaOI7kKolL3Bz670kXepoZ6X2fNA-he0pyrpQsnmDdupwRRnOtldQXaEoNlxmThl2OO9E6I4yJCbpJaU0Il1rIazThQmtTaDZFrwsXu9gGh8uhr3yHY43XMXRbDB00uxQSDh3epNgHGI9nvPrGroHQpjNwi65qaJK_O80ZWr0tfuYf2fLr_XP-sswcFYJlpdesAjACDFXcVAJKXgJTRWmUriRVNVRcaaJIUVNBmKik4HUx_mM8cKn4DD0eezd9_B182to2JOebBjofh2SZJLoQZNQyouSIuj6m1PvabvrQQr-zlNiDObs3Z_fm7MHcGHk4tQ9l66tz4F8V_wMIZWjn</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Prince, Patricia</creator><creator>Skornicki, Michelle</creator><creator>Suruki, Robert</creator><creator>Lee, Edward</creator><creator>Louder, Anthony</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20211201</creationdate><title>Economic burden of joint analysis in psoriasis: US claims analysis</title><author>Prince, Patricia ; Skornicki, Michelle ; Suruki, Robert ; Lee, Edward ; Louder, Anthony</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1442-be82daa94a91739d4ab3ba275b978d617fad3780705f14024d643f51939ea3673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Arthritis, Psoriatic - diagnosis</topic><topic>Arthritis, Psoriatic - epidemiology</topic><topic>Financial Stress</topic><topic>Humans</topic><topic>Insurance Claim Review</topic><topic>Psoriasis - diagnosis</topic><topic>Psoriasis - epidemiology</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Prince, Patricia</creatorcontrib><creatorcontrib>Skornicki, Michelle</creatorcontrib><creatorcontrib>Suruki, Robert</creatorcontrib><creatorcontrib>Lee, Edward</creatorcontrib><creatorcontrib>Louder, Anthony</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of managed care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Prince, Patricia</au><au>Skornicki, Michelle</au><au>Suruki, Robert</au><au>Lee, Edward</au><au>Louder, Anthony</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Economic burden of joint analysis in psoriasis: US claims analysis</atitle><jtitle>The American journal of managed care</jtitle><addtitle>Am J Manag Care</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>27</volume><issue>12</issue><spage>e406</spage><epage>e412</epage><pages>e406-e412</pages><issn>1088-0224</issn><eissn>1936-2692</eissn><abstract>Few studies have assessed the economic burden of concomitant joint disease in patients with psoriasis (PSO). This analysis compared health care resource utilization (HCRU) and health care costs in patients with PSO vs those with psoriatic arthritis (PsA).
This was a retrospective database analysis of US commercially insured patients with PSO or PsA.
Electronic health records (EHRs) and claims in Optum's deidentified Integrated Claims-Clinical data set from 2007 to 2018 were analyzed. Patients were followed up from the first PSO or PsA diagnosis for up to 5 years. Patients with claims or diagnosis codes in EHR data for PSO ("PSO only") were propensity score matched to patients with claims/diagnosis codes for both PSO and PsA ("PSO-PsA").
The matching algorithm generated 4418 matched patient pairs. During follow-up, PSO-PsA patients had greater HCRU than PSO-only patients, including more cumulative all-cause outpatient claims (P ≤ .05 at each year of follow-up). Mean total annual health care costs per patient were higher in PSO-PsA patients than PSO-only patients (PSO only: $14,546-$15,800 vs PSO-PsA: $21,581-$22,868; P < .05 at each year of follow-up). All-cause outpatient and pharmacy costs were also higher in the PSO-PsA cohort (P < .05 at each year of follow-up).
Comorbid joint disease in PSO is associated with greater costs and use of health care resources than PSO alone. These findings underscore the need for dermatologists to be vigilant about detection and treatment of joint symptoms. Early PsA diagnosis and therapy are crucial to improve patient outcomes and reduce the potential economic burden.</abstract><cop>United States</cop><pmid>34889582</pmid><doi>10.37765/ajmc.2021.88768</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1088-0224 |
| ispartof | The American journal of managed care, 2021-12, Vol.27 (12), p.e406-e412 |
| issn | 1088-0224 1936-2692 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2608540765 |
| source | ProQuest Central Essentials; Research Library; MEDLINE; ProQuest Central (Alumni Edition); ProQuest Central Student; Research Library (Alumni Edition); Research Library Prep; ProQuest Central Korea; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; ProQuest Central |
| subjects | Arthritis, Psoriatic - diagnosis Arthritis, Psoriatic - epidemiology Financial Stress Humans Insurance Claim Review Psoriasis - diagnosis Psoriasis - epidemiology Retrospective Studies |
| title | Economic burden of joint analysis in psoriasis: US claims analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T05%3A49%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Economic%20burden%20of%20joint%20analysis%20in%20psoriasis:%20US%20claims%20analysis&rft.jtitle=The%20American%20journal%20of%20managed%20care&rft.au=Prince,%20Patricia&rft.date=2021-12-01&rft.volume=27&rft.issue=12&rft.spage=e406&rft.epage=e412&rft.pages=e406-e412&rft.issn=1088-0224&rft.eissn=1936-2692&rft_id=info:doi/10.37765/ajmc.2021.88768&rft_dat=%3Cproquest_cross%3E2608540765%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2608540765&rft_id=info:pmid/34889582&rfr_iscdi=true |